Fujifilm India, a leading healthcare company, has announce the extension of its Tuberculosis (TB) Screening under its CSR campaign to Kutch District of Gujarat with its implementation Partner Apollo Telemedicine Network Foundation, further broadening the scope of its community health initiatives that are already underway in Valsad and Banaskantha.

This significant step aligns with the commitment to the national TB elimination campaign, "TB Harega Desh Jeetega," reinforcing the dedication to combatting TB across India.

The National TB Elimination Programme's India TB Report 2024 reveals that 25.55 lakh TB cases were notified last year, marking the highest number since the programme's inception in the 1960s.

Despite positive trends, the estimated number of TB cases remains high at 27.8 lakh in 2023. TB-related deaths remained unchanged at 3.2 lakh. These figures underscore the substantial TB burden in India and the need for sustained efforts to reduce both incidence and mortality.

Building on their past initiatives, Fujifilm India has successfully conducted numerous screenings and awareness programmes in Valsad and Banaskantha, reaching thousands of individuals and providing critical support in the fight against TB.

Since the inception of the TB screening CSR initiative in Gujarat, the company has been able to screen 8,218 individuals. Their innovative mobile TB diagnostic units, including the advanced FDR X-Air, have played a vital role in these efforts, ensuring that even the most remote communities get a comprehensive active case finding project of Tuberculosis.